Market Spotlight: Hidradenitis Suppurativa
|出版日期||內容資訊||英文 34 Pages
|焦點市場分析:化膿性汗腺炎 Market Spotlight: Hidradenitis Suppurativa|
|出版日期: 2019年11月07日||內容資訊: 英文 34 Pages||
This Market Spotlight report covers the Hidradenitis Suppurativa market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, key upcoming and regulatory events, probability of success, patent information, epidemiology, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
All of the approved drugs for hidradenitis suppurativa (HS) target tumor necrosis factor-alpha. These therapies are administered via the subcutaneous route, while Humira is also available in an intravenous formulation.
The majority of industry-sponsored drugs in active clinical development for HS are in Phase II. Therapies in development for HS target tumor necrosis factor-alpha, interleukin-17, interleukin-1, interleukin-23, JAK/STAT, and the C5a receptor. These therapies are administered via the oral, intravenous, and subcutaneous routes.
The only high-impact upcoming event in the HS space is topline Phase II trial results for avacopan. The overall likelihood of approval of a Phase I dermatology-general asset is 25.4%, and the average probability a drug advances from Phase III is 75.8%. Drugs, on average, take 8.1 years from Phase I to approval, compared to 8.0 years in the overall dermatology space.
There have been only seven licensing and asset acquisition deals involving HS drugs during 2014-19. The values have not been disclosed for any of these deals.
The distribution of clinical trials across Phase I-IV indicates that the majority of trials for HS have been in the early and midphases of development, with 83% of trials in Phase I-II, and only 17% in Phase III-IV.
The US has the lead in terms of the number of HS clinical trials globally. Germany leads the major EU markets, while Japan has the top spot in Asia.
Abbott has the highest number of completed clinical trials for HS, with two trials.
AbbVie is the only sponsor to have initiated a Phase III and Phase IV trial in HS.